Nuvalent, Inc.
NUVL
Rang in Aktien
#2111
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Aktienkurs
$123.96
Zuletzt synchronisiert: 2026-07-21
Marktkapitalisierung
$9.75B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
27.56%
Land
US
Handel Nuvalent, Inc. (NUVL)
Kategorie
Healthcare
Aktien-Split-Historie für Nuvalent, Inc. (NUVL)
Die Aktie Nuvalent, Inc. (Symbol: NUVL) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 21, 2026 statt.
Eine NUVL-Aktie, die vor dem Oct 21, 2026 gekauft wurde, entspricht heute 0 NUVL-Aktien.
Der letzte Aktiensplit fand am Oct 21, 2026 statt.
Eine NUVL-Aktie, die vor dem Oct 21, 2026 gekauft wurde, entspricht heute 0 NUVL-Aktien.
Liste der Aktiensplits
| Jahr | Aktien-Split | Multiplikator | Kumulierter Multiplikator |
|---|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | |||
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
| Unternehmen | Anzahl der Aktiensplits | Kumulierter Multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
